Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN – Get Rating) – Equities researchers at  Cantor Fitzgerald reduced their FY2023 earnings per share (EPS) estimates for Regeneron Pharmaceuticals  in a research note issued on  Monday, April 17th. Cantor Fitzgerald analyst O. Brayer now anticipates that the biopharmaceutical company will post earnings of $36.75 per share for the year, down from their prior estimate of $37.52. The consensus estimate for Regeneron Pharmaceuticals’ current full-year earnings is $34.05 per share.

A number of other research firms also recently weighed in on REGN. SVB Leerink upgraded Regeneron Pharmaceuticals from a “market perform” rating to an “outperform” rating in a research report on Monday, March 27th. SVB Securities upgraded Regeneron Pharmaceuticals from a “market perform” rating to an “outperform” rating and boosted their target price for the stock from $834.00 to $976.00 in a research report on Monday, March 27th. Raymond James upgraded Regeneron Pharmaceuticals from an “underperform” rating to a “market perform” rating in a research report on Thursday, March 23rd. Cowen upgraded Regeneron Pharmaceuticals from a “market perform” rating to an “outperform” rating and upped their price objective for the company from $775.00 to $875.00 in a report on Monday, January 30th. Finally, Bank of America upped their price objective on Regeneron Pharmaceuticals from $605.00 to $650.00 and gave the company an “underperform” rating in a report on Wednesday, March 29th. One analyst  has rated the stock with a sell rating, four have given a hold rating and nineteen have assigned  a buy rating to the stock. According to data from MarketBeat, Regeneron Pharmaceuticals  has an average rating of “Moderate Buy” and an average target price of $840.87.

REGN stock opened at $808.01 on Wednesday. The company has a market cap of $88.34 billion, a P/E ratio of 21.13, a PEG ratio of 2.44 and a beta of 0.23. Regeneron Pharmaceuticals has a twelve month low of $538.01 and a twelve month high of $837.55. The company has a quick ratio of 4.29, a current ratio of 5.06 and a debt-to-equity ratio of 0.12. The business has a fifty day moving average of $780.92 and a 200-day moving average of $751.99.

Regeneron Pharmaceuticals (NASDAQ:REGN – Get Rating) last posted its quarterly earnings data on Friday, February 3rd. The biopharmaceutical company reported $12.56 EPS for the quarter, topping analysts’ consensus estimates of $8.18 by $4.38. The company had revenue of $3.41 billion for the quarter, compared to analyst estimates of $3.11 billion. Regeneron Pharmaceuticals had a return on equity of 22.87% and a net margin of 35.64%. The business’s revenue was down 31.1% on a year-over-year basis. During the same quarter in the previous year, the firm earned $23.72 earnings per share.

In other Regeneron Pharmaceuticals news, EVP Marion Mccourt sold 1,100 shares of Regeneron Pharmaceuticals stock in a transaction on Wednesday, March 1st. The stock was sold at an average price of $759.89, for a total value of $835,879.00. Following the completion of the transaction, the executive vice president now directly owns 20,803 shares of the company’s stock, valued at approximately $15,807,991.67. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. In other Regeneron Pharmaceuticals news, EVP Marion Mccourt sold 1,100 shares of Regeneron Pharmaceuticals stock in a transaction on Wednesday, March 1st. The stock was sold at an average price of $759.89, for a total value of $835,879.00. Following the completion of the transaction, the executive vice president now directly owns 20,803 shares of the company’s stock, valued at approximately $15,807,991.67. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider George Yancopoulos sold 13,189 shares of Regeneron Pharmaceuticals stock in a transaction on Monday, February 6th. The shares were sold at an average price of $800.08, for a total value of $10,552,255.12. Following the completion of the transaction, the insider now directly owns 200,504 shares of the company’s stock, valued at $160,419,240.32. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 29,986 shares of company stock worth $23,933,592. Company insiders own  8.99% of the company’s stock.

Hedge funds and other institutional investors have recently modified their holdings of the business. PGGM Investments acquired a new position in shares of  Regeneron Pharmaceuticals in the 3rd quarter valued at about $30,775,000.  TrueWealth Advisors LLC purchased a new stake in shares of  Regeneron Pharmaceuticals in the third quarter worth approximately $207,000.  Ameritas Advisory Services LLC purchased a new stake in shares of  Regeneron Pharmaceuticals in the third quarter worth approximately $205,000.  Wipfli Financial Advisors LLC purchased a new stake in shares of  Regeneron Pharmaceuticals in the third quarter worth approximately $555,000.  Finally, Bank of Montreal Can raised its stake in shares of  Regeneron Pharmaceuticals by 54.6% in the fourth quarter. Bank of Montreal Can now owns 110,103 shares of the biopharmaceutical company’s stock worth $80,815,000 after purchasing an additional 38,901 shares during the last quarter. Institutional investors own  84.25% of the company’s stock.

Regeneron Pharmaceuticals, Inc is a biotechnology company, which engages in the discovery, invention, development, manufacture, and commercialization of medicines. Its product portfolio includes the following brands: EYLEA, Dupixent, Praluent, Kevzara, Libtayo, ARCALYST, and ZALTRAP. The firm accelerates the traditional drug development process through its proprietary VelociSuite technologies such as VelocImmune, which uses unique genetically-humanized mice to produce optimized fully-human antibodies and bispecific antibodies.

Receive News & Ratings for Regeneron Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regeneron Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.